Figure 1From: Clinical review: Drotrecogin alfa (activated) as adjunctive therapy for severe sepsis – practical aspects at the bedside and patient identificationType of infection and proposed delay between infection source control and drotrecogin alfa (activated) administration. CAP, community-acquired pneumonia; H, hour; OD, organ dysfunction; UTI, urinary tract infection.Back to article page